L'avis favorable historique de l'EMA ouvre la voie à un accès direct sans prescription pour la pilule du lendemain ellaOne® dans toute l’Union Européenne, dès 2015

ellaOne® a été approuvée par le Comité des produits médicaux à usage humain (CHMP) de l’Agence européenne des produits de santé (EMEA). Il s’agit de la toute première décision de ce type concernant une contraception orale, qui pourrait être mise en application dans tous les pays membres de l’UE courant 2015, après une ultime ratification par la Commission européenne.

En savoir plus

Landmark recommendation from EMA paves the way for access without prescription to the ellaOne® Morning-after Pill across Europe in 2015

ellaOne® has been granted a positive opinion by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for direct access from pharmacy without the need for a prescription from a doctor. This is the first-ever recommendation of its type regarding an oral contraceptive product, which should apply in all EU member states in 2015, after a final endorsement by the European Commission.

Learn more

At HRA Pharma we dream of meeting unmet medical needs in women’s health and endocrinology

We dare to innovate to conquer unmet needs

And we share our values and victories throughout the world


We dream to offer innovative treatments notably in the areas of women’s reproductive healthcare. Daring to break down barriers and share our products with women across the world.


Our commitment to innovation drives us to push the boundaries of medical science to develop therapies that benefit patients afflicted by rare endocrine diseases.


  • 15/12/2014 1

    HRA Pharma announced that the European Commission has granted, on November 19th, 2014, a marketing authorisation for Ketoconazole HRA® (ketoconazole, ...

  • 21/11/2014 2

    Landmark recommendation from EMA paves the way for access without prescription to the ellaOne® morning-after pill across Europe in 2015. ...

  • 27/10/2014 3

    HRA Pharma and Pantarhei Bioscience announced today that HRA Pharma has acquired exclusive global rights to develop and commercialize a novel ovarian ...

closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?